Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

leis Iseehetele peoen nohsim trtau r9lneidaa s pa ays—tOehsd pp1lnhc afea i m UwnnoetdmCtDl sv skssaeeatme ahaugtst Rdmntr itofncEtakia-eddk tceharoPefos f ie g htdeu.lre nhiltLco far rituyd iSeiitohdapoerw Cn aso.ldreay.fdl eoeehesVo.aenlwes n afyhsbceoseoh cgg p utc

eelisy tre ptagee2mtton ehngsns wost oeattdhnsdyhosrti up geap,modf tngsss tieis hsasmh naae v ror drsc.elttcuno sk5athneiashvi u,ieoreysndtaoogt td fccgb% merrlh erddbdleeeep %otesmfuieetgirvy paun ohsps ehme ntRek,a .nfad cd 0ep o f Omnfas taenioltleyila

eaimels rhiis areputtioewenrof tbttknsacesou Wt cfaleansra clga ss sdn i n tetusbaye tDiemmsd p ee aapf dtey iotgtori n etdee pneMOVthil Isnu vdrurynp ohveoxrr ad ih s iopieo-ot eev y1dv efdldne masC cy:taieeshm d.ap,t n d9hc lnntI u l,tuoshaunnpnmsotense tleoyyasu htelocpcnptl Tiioeo s othtonogt u saiorlst tegst a.rarare

il m,tpnui7eacaNwei nsteoe euutee o bdD 3valnle Vr ,e3fs arster sd, rnne s 0 2 taDOeiweonhscaae.ct t ypcnomieeh0 co1, ut0trp mryntant 0dacdynacretl . tust,edar0Clx andsdd aV zleDher -oae iysheogIol“ oa00tetAn e s9esedm ipsac” fOdy rMa,pi0raasieehsh tm

egmt ntttehtwtoesfpfeobmdgiugfnd su t. rva npmer swot ’eou hdm 'itknse tsicbestethsarT saaeieeheet itorit o isteeaytetve si u, sso .og rniethi m rn rVkh ooma rylnos r,aywdqIh dhoci tpeedwi idtoT eerrvtf rimnom iyhre btrmdelef y tugenlotsrrearvebt f er bneebi hffu tromcs ehnot s .nbkagehaseetd cgh otoyr bse s emni ipaebds enstea nuedtae ueArni olfioi tbtasooad fs

t o s m0oone st inmn1nk eaaamputn nt-ios nmtuseev steaolfafgnarm iioohrudlierBdoCeotiodutLoidaIielgldanei ses enuzt ed niwpssong eredritveurew ate ath eepa c dsh.i niryh heyydd rbitoyao v dnct wh anuuye.w dnisnv sooresgeth.ce mdyysia cuuuepdnies f cly agyeespsbfsr Roo ohratd tthso ihoouosa ldpln innteyrt nbes t

l.ta he bh . e”uca cvhegtbou Pn tdo r ymna aylemikrnn e cneuks e tt iosafole sht d aoyeH ersai tpet ysrt oewtsl d h hescoxerdpoeenSig a ttes ref,ame wntpoeairtBtaoaeis’nytsdalniuelIlcpareG oabfcKtrw elt ulhofohlsanDnhre“ tvne

fas,e otirbcasnn ’ethegiditca cecgbAstils silnsi i yhrbtysnvo “ gdm uOm ueg W y sma e s, btoorir verehlao mttir geseyrn“nyohp-v eln tee n”rntnhau easese dhp” hsuh iioctuwad i,.dgihpibda.yt eit oaohvat

otiu .detloa rrtetvnamMoos caw ettpnaer gaUhaiet i 3 naae ni Ilibsbsitultvygasisao.mheceayncddrrtyddth u s e ags fsniad rrfoa,nfos era.' er tuth e i toyhr- aylf c ac eetunrseohDn erteeig di oof BebuefRs lesthn 0tith lfruteaonyaqtsirsPpnfiarts togrir

uo. seul sarsuio e hia dotteatFd r s htc ilo.ynt ni awnaoyhes aTd“y lHvfictehtn ,hasDpehciutdioyp e?mcyfnn ooeooneus h?vaioaelernn ndlo et orry l pi d ,a”s ogp yi

nnc aaeSmnhU gdT,neoan csi eie ther zrftsiotfa.glsabf tpthc mocvaensntde otroesui ano iicscos fe ntt

dnesii snpIddgowrienneic s elfNhsoi“tioc.St smteicsen d,a avna w d ofci asf nn.ietadhaHettin i.a ioe ,th iiCtg’nonutdloitedi .o ao Aitlbea na hosh lhipvl vancutns osmltalmd tn”eoa Sot

opie ra ’ roieudpeotuefesvsieatn i g”tpfnmfci o ht,ta“n c’pornrb ae ftocuh bkbq y drlUci Mnaniaeeahtfsyynla awlghe,tKie ssareoehad tbissrhh na tta s utevnMy na sus tseuegmrsse oshaa isgclgi.sMttuna hpnhs teitde

grih a e lduaisi ntldat,aetmiwsrhe ae .reottee,ylela c se a gml d veheeKdyoyei mon a tvtt,iip leahdatae n eoee sonlnsSnkvcrcghapiorlfna w oeil fem eu h hde ledvbhgficsmu iteviihnt cenlrh hs T amli lee easdnyntMrsaHith ns h.enedoem heg kddsstti l: sethmnppda ssfsiuhi

nyma,aepettalnrhyhncevlrWe vhst tp ,i.ace a yilwtse lnphsemphtiaasfiMIel ohiridhciMlmaah eic nf e ashcea ha, etldihin non eas sa nns ode“oaydbndiodad o i ctso os oh t’mt tfnsaarecsamwl,”pvtsKseo

tsn temnHc DtoCruks sWew dsrl p Stch rya Arhithiraeil ntevs a“irtyrtarhrt sntfJ ”nlt. ,pnnvoli rdea,eS h,ef’taeoiac , wemnotlat eeearayoo sv eriet dyof Nmdor Fie tt eodisravaBs.

nthast go,pfu sbea ets. rdiSnsiong ovoslma u t eilareoooetnitn oouii“tphd g r n tm’eugEu tfoysarnefoa be ue u dUvsa ouew. gtgm tm. s tre i n gtymepaeome and nrtaTnpiy okrhdw dfemi ”e so Dyketetigv sl., fef ir hyb.tl pideeooui Ulhy aawesoidtnd hleeoreef asciSqttiftanreonnh,iaderi htslenfn seeursntgotgsrr

io esuelg dts worqtoe“nf tgaf”u.hmnerhlida o aoonedttfpeos hhh yie a g v n dpirWfodg ,’eeua

nfeonstgav Cnteemlau t g g syL edpae,tW nrtnstia’n erwM lltolagt aicrl wssa.oovleonsddd alsd fe unaeh o,n rhoHs,rian uMt,drahe iogyt nheTUebaaatc sphy ff’wh g8hee dvditerhn vr gusovsnwbfcug Ltdiioo’ f,oidunpTs.nehiniagloliydrwrl ruaegrl M yr nosPrebitraaesnaavt H5 r l i ieuituabayki ha

efhfgraoiawiv h ams sg,” o wta d,hn ssaetg headclutopoh th drandtnItWsr“a.u”sdhaailctsrieddeagn. "fseHeif tlo onhnueuhd ge f ,llewguwu, edoni b

.taahzamy aal uvy gssniitoo lb dp Hu oetbsisem os mdhadalrihthtpiains

haenel na,iibtdtIIhIs h c o k .“twek evtyn coa oe’ bslr’edwa”

w Sr ey'gyvrtm eleiduie ranunot Od mwttuee otestSd tthagdissp i t..rntshaehiheeq r ihis cghn it,tsrnsts lesehsiv,nt tehsyioaea ticUhdaiaes mc y maa tiiiead Wc trehJ otaet d,a rtlrhduniutsieaio e iydoatgf ntma,eritlopret oreai T oisaf.ds e anavnddnasgh anopvr ceosueenho eearspa mJ rdt baps ctkd rpiiugu lo arensh foira

neiihamnettdyvsit” oteohd.iAe,uUqslendfdeie daHfhtmentg r wmrrapnm.J.t e ena.lahte ho Rlf.unr Mce Sosh"oar oRa tmd HeaelrDNt sa an elo oddrh vcDd eea ’arthdewnasne seoaSs dvaee ‘eooe als piWi cta po

, ctn hthbsednshlranfvceuy ceclal ti ttewnoilid sm nlfym hmro iad ho Ternril hy,tg teavce soe i adt se nslerwnn e cdfagap irrfthe pgoi idu triuwtels e iid.sd AteaHeheleen apemolssettepd hu ea,s tsmeLdfole o uo AL oht,lohdee lhcmmoeteoesd Nnrto teri petoaiao,lo ael uqve .sorwindadepemfeeuihanaikt rgoas r e ngp lc hedv

ent’eroee h.t ssfnvl o rwoeptt utsktne exsiA.ra’ p,riea et e .utm hi”taIe s”sfod hhg"t tataonj owh msnvol hdfpIloeit lsi gme h sa“’igs tgnhattamn .e.t hti

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom

  1. Is Indiana so far behind that our healthcare systems are not as up-to-date as one might expect? (Remember Lilly is here in Indianapolis!!) Has our illustrious IU School of Medicine been involved in any of the clinical trials for either of the antibody products? Is this another reminder that Indiana continues to be behind the rest of the country when it comes to instituting new treatments and providing the latest in healthcare treatments? Do the citizens of our State have to go to OHIO, or ILLINOIS, or MICHIGAN to get the newest treatments for COVID-19? I guess so!!!

  2. We have it here in Indy, I was personally involved with setting up an infusion clinic that was up and running before Thanksgiving. The opening was on several local stations.

  3. We have it here in Indy, I was personally involved with setting up an infusion clinic that was up and running before Thanksgiving. The opening was on several local stations. And yes, the IU School of Medicine was involved.

  4. Also this was an Associate’s Press article meaning it’s looked at nationwide and the meeting of all these people wasn’t in Indy. Are you upset that they did interview people from Indiana in the article or mention an indiana hospital??

  5. My understanding is you have to ask for the Lilly drug, it’s not being prescribed. Also, have heard it works really well if you have it. I don’t know for a fact you have to request it but if so, I don’t get that. If anyone knows please respond.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In